AI assistant
Sending…
Sana Biotechnology, Inc. — Director's Dealing 2021
Feb 4, 2021
32303_dirs_2021-02-03_dd0be3c8-9cf1-4972-a1a7-5f7bef184dc8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Sana Biotechnology, Inc. (SANA)
CIK: 0001770121
Period of Report: 2021-02-03
Reporting Person: Bishop Hans Edgar (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3705000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A-1 Convertible Preferred Stock | $ | Common Stock (1075000) | Direct | ||
| Series A-2 Convertible Preferred Stock | $ | Common Stock (800000) | Direct | ||
| Series B Convertible Preferred Stock | $ | Common Stock (156250) | Direct |
Footnotes
F1: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering.
F2: The expiration date is not relevant to the conversion of these securities.
More from Sana Biotechnology, Inc.
Regulatory Filings
2026
Jun 5
Capital/Financing Update
2026
May 15
Share Issue/Capital Change
2026
May 11
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Board/Management Information
2026
Apr 24
Capital/Financing Update
2026
Apr 13
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 4
Capital/Financing Update
2026
Mar 3